Beacon Investment Advisory Services Inc. Sells 33,261 Shares of Insulet Corporation $PODD

Beacon Investment Advisory Services Inc. reduced its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 27.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 88,630 shares of the medical instruments supplier’s stock after selling 33,261 shares during the period. Insulet comprises 1.2% of Beacon Investment Advisory Services Inc.’s portfolio, making the stock its 25th biggest position. Beacon Investment Advisory Services Inc. owned about 0.13% of Insulet worth $27,846,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Zions Bancorporation National Association UT bought a new stake in Insulet during the 1st quarter valued at $26,000. Larson Financial Group LLC raised its position in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. SouthState Corp raised its position in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares in the last quarter. Kozak & Associates Inc. bought a new stake in Insulet during the 2nd quarter valued at $32,000. Finally, Ramirez Asset Management Inc. bought a new stake in Insulet during the 1st quarter valued at $53,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They set a “buy” rating and a $365.00 target price for the company. Royal Bank Of Canada lifted their price target on Insulet from $330.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 8th. The Goldman Sachs Group started coverage on Insulet in a report on Friday, May 30th. They issued a “buy” rating and a $380.00 price target on the stock. Citigroup reiterated a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Finally, Barclays lifted their price target on Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $343.06.

Insulet Stock Down 0.3%

Insulet stock opened at $326.97 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The business’s 50-day simple moving average is $317.53 and its two-hundred day simple moving average is $295.53. The company has a market cap of $23.02 billion, a PE ratio of 99.38, a PEG ratio of 2.72 and a beta of 1.36. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Activity

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.